Results 71 to 80 of about 6,667 (221)

Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

open access: yesBioengineering, 2018
Pediatric high-grade glioma (pHGG) and brainstem gliomas are some of the most challenging cancers to treat in children, with no effective therapies and 5-year survival at ~2% for diffuse intrinsic pontine glioma (DIPG) patients.
Cavan P. Bailey   +4 more
doaj   +1 more source

Leptomeningeal disease and tumor dissemination in a murine diffuse intrinsic pontine glioma model: Implications for the study of the tumor-cerebrospinal fluid-ependymal microenvironment [PDF]

open access: yes, 2022
BACKGROUND: Leptomeningeal disease and hydrocephalus are present in up to 30% of patients with diffuse intrinsic pontine glioma (DIPG), however there are no animal models of cerebrospinal fluid (CSF) dissemination.
Chen, Hong   +11 more
core   +2 more sources

Crossing the Blood–Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
Molecularly imprinted polymeric nanocarriers (nanoMIPs) offer robust, antibody‐mimetic platforms to overcome the blood‐brain barrier. The article surveys nanoMIP design and ligand‐directed surface engineering that harness receptor‐mediated transcytosis, and highlights therapeutic and diagnostic applications in neurodegeneration, brain tumors and ...
Ranjit De, Shuliang Shi, Kyong‐Tai Kim
wiley   +1 more source

FUS BBBO with a Portable FUS System and real time mapping

open access: yesAlzheimer's &Dementia, Volume 21, Issue S2, December 2025.
Abstract Background Treatment of neurological diseases has been at the forefront of medical research for more than a century with limited success due partly to the blood‐brain barrier (BBB) that impedes both delivery and biodistribution of the drug delivered.
Elisa Konofagou
wiley   +1 more source

Can Focused Ultrasound Overcome the Failure of Chemotherapy in Treating Pediatric Diffuse Intrinsic Pontine Glioma Due to a Blood–Brain Barrier Obstacle?

open access: yesPharmaceuticals
Background: The blood–brain barrier (BBB) plays an important role in regulating homeostasis of the central nervous system (CNS), and it is an obstacle for molecules with a molecular weight higher than 500 Da seeking to reach it, making many drugs ...
Silvana Filieri   +8 more
doaj   +1 more source

Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults

open access: yesFrontiers in Oncology, 2023
Gliomas are the most common primary central nervous system (CNS) tumors and a major cause of cancer-related mortality in children (age <15 years), adolescents and young adults (AYA, ages 15–39 years), and adults (age >39 years). Molecular pathology
Annette Weiser   +11 more
doaj   +1 more source

DIPG-10. TP53 PATHWAY ALTERATION IS DRIVING RADIORESISTANCE IN DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)

open access: yesNeuro-Oncology, 2019
Diffuse intrinsic pontine gliomas (DIPG) are the most severe pediatric brain tumours. Though accepted as the main therapeutic, radiotherapy is only transiently efficient and not even in every patient. We previously identified an heterogeneous response to radiotherapy at diagnosis depending on the type of histone H3 mutated (Castel et al., 2015).
Werbrouck, Coralie   +14 more
openaire   +3 more sources

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG) [PDF]

open access: yesJournal of Visualized Experiments, 2017
Diffuse Intrinsic Pontine Glioma (DIPG) is a childhood brainstem tumor that carries a universally fatal prognosis. Because surgical resection is not a viable treatment strategy and biopsy is not routinely performed, the availability of patient samples for research is limited. Consequently, efforts to study this disease have been challenged by a paucity
Lin, Grant L., Monje, Michelle
openaire   +2 more sources

A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors

open access: yesCancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Fimepinostat, an oral dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol‐4,5‐bisphosphate 3‐kinase (PI3K), has shown activity in preclinical models of Myc‐driven pediatric malignancies. This Phase 1 trial aimed to determine the recommended pediatric Phase 2 dose (RPP2D), describe the toxicity profile, and evaluate
David S. Shulman   +13 more
wiley   +1 more source

Revisiting the Incidence of Hypercalcemia in Contemporary Diagnoses of Pediatric Patients With Solid Tumors

open access: yesPediatric Blood &Cancer, Volume 72, Issue 12, December 2025.
ABSTRACT Background Hypercalcemia is rarely observed in pediatric patients with cancer. However, rare cases of renal insufficiency and osteoporosis have been reported as severe consequences. Published literature focuses predominantly on hypercalcemia in pediatric hematologic malignancies, precluding causative associations with solid tumor disease ...
Felicia Y. Ho   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy